Core Viewpoint - The company is expected to turn profitable in 2025, with a projected net profit attributable to shareholders ranging from 0.88 billion to 1.32 billion yuan, driven by improvements in its subsidiaries' operations [1] Group 1: Financial Performance - The company anticipates a significant turnaround in profitability for the year 2025, with a net profit forecasted between 0.88 billion and 1.32 billion yuan, marking a year-on-year recovery [1] - The official annual report has not yet been announced [1] Group 2: Management Changes - On February 5, 2026, the company announced that employee stockholding platforms and some directors and executives plan to reduce their holdings by up to 2.99% of the total share capital, through centralized bidding or block trading [2] Group 3: Business Development - The company is accelerating its toothpaste OEM business and deepening cooperation with sensitive toothpaste brands, while also seeing significant growth in its online channels for its own brand [3] - The investment target, Weimei Zi, is maintaining high growth in Douyin GMV for 2025, and the commercialization of the AKK bacteria products from Shan'en Kang is expected to contribute to performance [3] Group 4: Institutional Perspectives - Some brokerages released reports on February 7, 2026, maintaining an "outperforming the industry" rating and raising the target price to 48 yuan, but noted the need to monitor profitability pressures and the impact of trade frictions [4] Group 5: Stock Performance - As of February 10, 2026, the stock price closed at 40.97 yuan, down 2.06% for the day, with a net outflow of 603,500 yuan in principal funds, but the cumulative increase for the year reached 36.20% [5] - There is an intensifying tug-of-war between bulls and bears, necessitating caution regarding short-term profit-taking pressures [5]